Earnings Feed
Start Free
Home/Filings/4/0000899243-18-007294
4//SEC Filing

Christianson Gary 4

Accession 0000899243-18-007294

CIK 0001412067other
View on SEC.govCompany Profile

Filed

Mar 12, 8:00 PM ET

Accepted

Mar 13, 6:02 PM ET

Size

36.0 KB

Accession

0000899243-18-007294

Insider Transaction Report

Form 4
Period: 2018-03-09
Cascadian Therapeutics, Inc.CASC
Christianson Gary
Chief Operating Officer
Transactions
  • Disposition to Issuer

    Restricted Stock Units

    2018-03-09−11,300→ 0 total
    → Common Stock (11,300 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2018-03-09−15,000→ 0 total
    → Common Stock (15,000 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2018-03-09−164,500→ 0 total
    → Common Stock (164,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2018-03-09−25,000→ 0 total
    Exercise: $10.44Exp: 2021-12-12→ Common Stock (25,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2018-03-09−16,667→ 0 total
    Exercise: $10.56Exp: 2022-12-16→ Common Stock (16,667 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2018-03-09−51,200→ 0 total
    Exercise: $4.64Exp: 2027-01-11→ Common Stock (51,200 underlying)
  • Disposition from Tender

    Common Stock

    2018-03-09−6,515→ 0 total
  • Disposition to Issuer

    Stock Option (Right to buy)

    2018-03-09−8,334→ 0 total
    Exercise: $19.92Exp: 2018-12-01→ Common Stock (8,334 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2018-03-09−8,334→ 0 total
    Exercise: $41.52Exp: 2019-12-01→ Common Stock (8,334 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2018-03-09−8,334→ 0 total
    Exercise: $28.44Exp: 2020-12-12→ Common Stock (8,334 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2018-03-09−41,667→ 0 total
    Exercise: $21.06Exp: 2023-09-24→ Common Stock (41,667 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2018-03-09−41,667→ 0 total
    Exercise: $6.90Exp: 2024-05-17→ Common Stock (41,667 underlying)
  • Disposition to Issuer

    Stock Option (Right to buy)

    2018-03-09−68,000→ 0 total
    Exercise: $3.99Exp: 2027-09-18→ Common Stock (68,000 underlying)
Footnotes (21)
  • [F1]Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
  • [F10]Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $129,167.70, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.
  • [F11]25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months.
  • [F12]Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $274,432.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.
  • [F13]25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months.
  • [F14]Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $408,680.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.
  • [F15]Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $113,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
  • [F16]The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years.
  • [F17]The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.
  • [F18]Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $150,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
  • [F19]The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years.
  • [F2]25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2010, and the remainder vest monthly thereafter for 36 months.
  • [F20]Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $1,645,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
  • [F21]The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years.
  • [F3]Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price.
  • [F4]25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2011, and the remainder vest monthly thereafter for 36 months.
  • [F5]25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2012, and the remainder vest monthly thereafter for 36 months.
  • [F6]25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2013, and the remainder vest monthly thereafter for 36 months.
  • [F7]25% of the shares subject to the option vest on the first anniversary of the grant date of December 16, 2014, and the remainder vest monthly thereafter for 36 months.
  • [F8]25% of the shares subject to the option vest on the first anniversary of the grant date of September 24, 2015, and the remainder vest monthly thereafter for 36 months.
  • [F9]25% of the shares subject to the option vest on the first anniversary of the grant date of May 17, 2016, and the remainder vest monthly thereafter for 36 months.

Documents

1 file

Issuer

Cascadian Therapeutics, Inc.

CIK 0001412067

→
Entity typeother

Related Parties

1
  • filerCIK 0001418881

Filing Metadata

Form type
4
Filed
Mar 12, 8:00 PM ET
Accepted
Mar 13, 6:02 PM ET
Size
36.0 KB
View on SEC.gov